-Through 48 Weeks, Biktarvy Found to Be Non-Inferior to
Abacavir-Containing Regimen in Virologically Suppressed Adults Living
– No Patients in Biktarvy Treatment Arm Demonstrated
Treatment-Emergent Resistance Through 48 Weeks –
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mar. 5, 2018--
Gilead Sciences, Inc. (NASDAQ: GILD) today announced detailed 48-week
results from a Phase 3 study (Study 1844) evaluating the efficacy and
safety of switching from a regimen containing abacavir, dolutegravir and
lamivudine (600/50/300mg) (ABC/DTG/3TC) to Biktarvy®
(bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg), a
once-daily single tablet regimen, in virologically suppressed adults
with HIV. Through Week 48, Biktarvy was found to be statistically
non-inferior to ABC/DTG/3TC with a numerically lower incidence of mild
or moderate study drug-related adverse events and no treatment-emergent
resistance. The data were presented at the 2018 Conference on
Retroviruses and Opportunistic Infections (CROI) in Boston (Session
“In this study, Biktarvy maintained high rates of virologic suppression
and demonstrated a high barrier to resistance through 48 weeks of
treatment, findings that have been consistently observed across all
Phase 3 studies of the regimen,” said Jean-Michel Molina, MD, Head of
the Infectious Diseases Department, Hospital Saint Louis, Paris, France
and lead study investigator. “In addition, people taking Biktarvy
experienced fewer drug-related adverse events compared to participants
in the comparator arm, a consideration for physicians and their patients
who choose to switch HIV treatments.”
Biktarvy is indicated as a complete regimen for the treatment of HIV-1
infection in adults who have no antiretroviral treatment history or to
replace the current antiretroviral regimen in those who are
virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral
regimen for at least three months with no history of treatment failure
and no known substitutions associated with resistance to the individual
components of Biktarvy. No dosage adjustment of Biktarvy is required in
patients with estimated creatinine clearance greater than or equal to 30
mL per minute. Biktarvy has a Boxed Warning in its product label
regarding the risk of post treatment acute exacerbation of hepatitis B.
See below for Important Safety Information.
In Study 1844, a total of 563 virologically suppressed adults with HIV
taking a regimen of ABC/DTG/3TC were randomized 1:1 in a blinded fashion
to continue a once-daily fixed-dose combination of ABC/DTG/3TC or to
switch to Biktarvy. At the primary endpoint of Week 48, switching to
Biktarvy was non-inferior to continuing ABC/DTG/3TC with 1.1 percent in
the Biktarvy arm and 0.4 percent in the ABC/DTG/3TC arm having HIV-1 RNA
≥50 c/mL (difference: 0.7 percent; 95 percent CI: -1.0 percent to 2.8
percent, p=0.62); the proportion of patients with HIV-1 RNA <50 c/mL was
93.6 percent in the Biktarvy arm and 95.0 percent in the ABC/DTG/3TC
arm, according to FDA snapshot algorithm.
Patients in the Biktarvy arm had a lower incidence of study drug-related
adverse events than those in the ABC/DTG/3TC arm (8 percent vs. 16
percent, p=0.006; all grades), which were primarily mild or moderate in
severity. The difference between groups was primarily driven by
numerically more drug-related gastrointestinal (flatulence, nausea,
diarrhea) and neuropsychiatric (abnormal dreams and insomnia) adverse
events in the ABC/DTG/3TC arm. The most common study drug-related
adverse event was headache (3 percent in both arms). Few participants
had adverse events leading to premature study discontinuation (2 percent
vs. 1 percent).
Through Week 48, no patients in either treatment arm developed
treatment-emergent resistance. In addition, there were no renal adverse
events leading to discontinuations and no cases of proximal renal
tubulopathy in either treatment group. At Week 48, lipid profiles were
unchanged after switching to Biktarvy from ABC/DTG/3TC, and bone mineral
density changes from baseline were the same between arms.
“The data presented at CROI this week, in addition to previously
reported studies in both treatment-naïve and virologically suppressed
adult patients, further demonstrate that Biktarvy may be appropriate for
a wide range of people living with HIV who are either new to treatment
or who choose to switch regimens,” said Norbert W. Bischofberger, PhD,
Gilead’s Executive Vice President, Research and Development and Chief
Scientific Officer. “Following the recent approval of Biktarvy in the
United States, we look forward to working to expand the availability of
this novel therapy to patients around the world.”
Biktarvy was approved by the United States Food and Drug Administration
(FDA) on February 7, 2018. A marketing authorization application for
Biktarvy is under review in the European Union.
Additional clinical trials of Biktarvy are ongoing, including a
dedicated study in women, as well as a study in adolescents and children
living with HIV. Data from the women’s study (Study 1961) and a cohort
of adolescent subjects enrolled in the pediatric study (Study 1474) are
being presented in poster sessions (Posters 2539 and 2271) at CROI.
Biktarvy does not cure HIV infection or AIDS.
Important U.S. Safety Information for Biktarvy
BOXED WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B
Severe acute exacerbations of hepatitis B have been reported in
patients who are coinfected with HIV-1 and HBV and have discontinued
products containing emtricitabine (FTC) and/or tenofovir disoproxil
fumarate (TDF), and may occur with discontinuation of Biktarvy.
Closely monitor hepatic function with both clinical and laboratory
follow-up for at least several months in patients who are coinfected
with HIV-1 and HBV and discontinue Biktarvy. If appropriate,
anti-hepatitis B therapy may be warranted.
Coadministration: Do not use Biktarvy with dofetilide or
Warnings and precautions
Drug interactions: See Contraindications and Drug Interactions
sections. Consider the potential for drug interactions prior to and
during Biktarvy therapy and monitor for adverse reactions.
Immune reconstitution syndrome, including the occurrence of
autoimmune disorders with variable time to onset, has been reported.
New onset or worsening renal impairment: Cases of acute renal
failure and Fanconi syndrome have been reported with the use of
tenofovir prodrugs. In clinical trials of Biktarvy, there have been no
cases of Fanconi syndrome or proximal renal tubulopathy (PRT). Do not
initiate Biktarvy in patients with estimated creatinine clearance
(CrCl) <30 mL/min. Patients with impaired renal function and/or taking
nephrotoxic agents (including NSAIDs) are at increased risk of
renal-related adverse reactions. Discontinue Biktarvy in patients who
develop clinically significant decreases in renal function or evidence
of Fanconi syndrome.
Renal monitoring: Prior to or when
initiating Biktarvy and during therapy, assess serum creatinine, CrCl,
urine glucose, and urine protein in all patients as clinically
appropriate. In patients with chronic kidney disease, also assess
Lactic acidosis and severe hepatomegaly with steatosis: Fatal
cases have been reported with the use of nucleoside analogs, including
FTC and TDF. Discontinue Biktarvy if clinical or laboratory findings
suggestive of lactic acidosis or pronounced hepatotoxicity develop,
including hepatomegaly and steatosis in the absence of marked
Most common adverse reactions (incidence ≥5%; all grades) in
clinical studies were diarrhea (6%), nausea (5%), and headache (5%).
Prescribing information: Consult the full prescribing
information for Biktarvy for more information on Contraindications,
Warnings, and potentially significant drug interactions, including
Enzymes/transporters: Drugs that induce P-gp or induce both
CYP3A and UGT1A1 can substantially decrease the concentration of
components of Biktarvy. Drugs that inhibit P-gp, BCRP, or inhibit both
CYP3A and UGT1A1 may significantly increase the concentrations of
components of Biktarvy. Biktarvy can increase the concentration of
drugs that are substrates of OCT2 or MATE1.
Drugs affecting renal function: Coadministration of Biktarvy
with drugs that reduce renal function or compete for active tubular
secretion may increase concentrations of FTC and tenofovir and the
risk of adverse reactions.
Dosage and administration
Dosage: 1 tablet taken once daily with or without food.
Renal impairment: Not recommended in patients with CrCl <30
Hepatic impairment: Not recommended in patients with severe
Prior to or when initiating: Test patients for HBV infection.
Prior to or when initiating, and during treatment: As
clinically appropriate, assess serum creatinine, CrCl, urine glucose,
and urine protein in all patients. In patients with chronic kidney
disease, assess serum phosphorus.
Pregnancy and lactation
Pregnancy: There is insufficient human data on the use of
Biktarvy during pregnancy. An Antiretroviral Pregnancy Registry (APR)
has been established. Available data from the APR for FTC shows no
difference in the rates of birth defects compared with a US reference
Lactation: Women infected with HIV-1 should be instructed not
to breastfeed, due to the potential for HIV-1 transmission.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops
and commercializes innovative therapeutics in areas of unmet medical
need. The company’s mission is to advance the care of patients suffering
from life-threatening diseases. Gilead has operations in more than 35
countries worldwide, with headquarters in Foster City, California.
For nearly 30 years, Gilead has been a leading innovator in the field of
HIV, driving advances in treatment, prevention, testing and linkage to
care, and cure research. Today, it’s estimated that more than 10 million
people living with HIV globally receive antiretroviral therapy provided
by Gilead or one of the company’s manufacturing partners.
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 that are
subject to risks, uncertainties and other factors, including the risk
that physicians may not see the benefits of prescribing Biktarvy for the
treatment of HIV. In addition, the European Union and other regulatory
authorities may not approve Biktarvy in the currently anticipated
timelines or at all, and any marketing approvals, if granted, may have
significant limitations on their use. These risks, uncertainties and
other factors could cause actual results to differ materially from those
referred to in the forward-looking statements. The reader is cautioned
not to rely on these forward-looking statements. These and other risks
are described in detail in Gilead’s Annual Report on Form 10-K for the
year ended December 31, 2017, as filed with the U.S. Securities and
Exchange Commission. All forward-looking statements are based on
information currently available to Gilead, and Gilead assumes no
obligation to update any such forward-looking statements.
U.S. full prescribing information for Biktarvy, including BOXED
WARNING, is available at www.gilead.com.
Biktarvy is a trademark of Gilead Sciences, Inc., or its related
For more information on Gilead Sciences, please visit the company’s
website at www.gilead.com,
follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs
at 1-800-GILEAD-5 or 1-650-574-3000.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180305005902/en/
Source: Gilead Sciences, Inc.
Gilead Sciences, Inc.
Sung Lee, 650-524-7792